Robert Azelby, EVP & Chief Commercial Officer at Juno Therapeutics, Inc. (JUNO), sold 205,078 shares at $86.25 ($17.7M) on 2018-01-22, disclosed to the SEC on 2018-01-24.
Open-market sale of $17.7M JUNO by EVP & Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $86.25 | 102,539 | $8.8M | 50.0% |
| 2 | $86.25 | 102,539 | $8.8M | 50.0% |
| Total | $86.25 avg | 205,078 | $17.7M | 100% |
| Filing → |
| JUNO | SELL | 2018-02-14 | $356K | — | Filing → |
| JUNO | SELL | 2018-02-09 | $600K | — | Filing → |
| JUNO | SELL | 2018-02-02 | $715K | — | Filing → |